The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis

Trial Profile

The beneficial effect and safety Eldecalcitol with combined peginterferon alpha-2a plus ribavirin for chronic hepatitis C patients with osteoporosis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Eldecalcitol (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top